LDL-Receptor Mediated Drug Targeting to Malignant Tumors in the Brain
Malignant tumors are composed of abnormal cells that usually grow very aggressively. It is extremely difficult to treat many of these malignant tumors with conventional methods, including surgical resection, radiation therapy, chemotherapy and combinations of these modalities. To enhance the efficacy of tumor treatment with chemotherapy, targeted drug delivery resulting in high concentrations of therapeutic compounds in tumor cells and relatively low concentrations in neighboring normal cells has been attractive and many approaches for drug targeting have been extensively evaluated.
KeywordsCholesteryl Ester Target Drug Delivery Boron Neutron Capture Therapy Intermediate Density Lipoprotein Biomedical Aspect
Unable to display preview. Download preview PDF.
- 1.Danik M, Champagne D, Petit-Turcotte C, Beffert U and Poirier J. Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit. Rev. Neur. 1999; 13 (4): 357–407Google Scholar
- 3.Murakami M, Ushio Y, Mihara Y, Kuratsu J, Horiuchi S, Morino Y. Cholesterol uptake by human glioma cells via receptor-mediated endocytosis of low-density lipoprotein J Neurosurg 1990 73 (5): 760–767Google Scholar
- 4.Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 2000; 60 (8): 2300–2303Google Scholar
- 10.Nakagawa T, Ueyama Y, Nozaki S, Yamashita S, Menju M, Funahashi T, KamedaTakemura K, Kubo M, Tokunaga K, Tanaka T, et al. Marked hypocholesterolemia in a case with adrenal adenoma-enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. J Clin Endocrinol Metab 1995; 80 (1): 92–96CrossRefGoogle Scholar
- 15.Lu DR and Ji B. Carborane containing cholesterol, a new type of molecule for targeted boron drug delivery. U.S. Patent No. 09 /609, 957, (2001)Google Scholar
- 18.Shawer M, Greenspan P, Q ie S and Lu DR. VLDL-resembling phospholipidsubmicron emulsion for cholesterol-based drug targeting. J. Pharm. Sci. 2002 (In press)Google Scholar
- 20.Lundberg S. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res 1987; 47: 4105–4108Google Scholar
- 21.Lestavel-Delattre S, Martin-Nizard F, Clayey V, Testard P, Favre G, Doualin G et. al. Low Density Lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res 1992; 52: 3629–3635Google Scholar
- 26.Laster B H, Kahl S B, Popenoe E A, Pate D W and Fairchild R G. Biological efficacy of boronated low-density lipoprotein for boron neutron capture therapy as measured in cell culture. Cancer Res 1991; 51: 4588–4593Google Scholar
- 27.De Smidt P C and van Berkel T J. Prolonged serum half life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res 1990; 50: 7476–7482Google Scholar
- 28.Vitols S, Soderberg-Reid K, Masquelier M, Sjostrom B and Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer 1990; 62(5): 724729Google Scholar